Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Westerberg

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Pharmacoepidemiology and Drug Safety|March 15, 2023
Design considerations for observational studies of drugs for advanced cancerXabier Garcia-Albeniz, Pär Stattin, Marcus Westerberg, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
JAMA Network Open|May 6, 2025
Radical Treatment for Prostate Cancer in Men With Limited Life Expectancy in SwedenEugenio Ventimiglia, Rolf Gedeborg, Johan Styrke, et al.
JAMA Network Open|May 17, 2021
Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year CohortOskar Bergengren, Marcus Westerberg, Lars Holmberg, et al.
JNCI Cancer Spectrum|February 6, 2025
Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillanceChristian Corsini, Pietro Scilipoti, Andri Wilberg Orrason, et al.
JAMA Network Open|October 2, 2023
Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet TherapyChristian Corsini, Hans Garmo, Andri Wilberg Orrason, et al.
BJU International|April 11, 2020
Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in SwedenAndri Wilberg Orrason, Marcus Westerberg, Hans Garmo, et al.
Scandinavian Journal of Urology|March 17, 2026
Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based studyPaolo Zaurito, Rolf Gedeborg, Hans Garmo, et al.
Acta Oncologica (Stockholm, Sweden)|September 19, 2019
Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based studyMarcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Pharmacoepidemiology and Drug Safety|March 15, 2023
Design considerations for observational studies of drugs for advanced cancerXabier Garcia-Albeniz, Pär Stattin, Marcus Westerberg, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
JAMA Network Open|May 6, 2025
Radical Treatment for Prostate Cancer in Men With Limited Life Expectancy in SwedenEugenio Ventimiglia, Rolf Gedeborg, Johan Styrke, et al.
JAMA Network Open|May 17, 2021
Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year CohortOskar Bergengren, Marcus Westerberg, Lars Holmberg, et al.
JNCI Cancer Spectrum|February 6, 2025
Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillanceChristian Corsini, Pietro Scilipoti, Andri Wilberg Orrason, et al.
JAMA Network Open|October 2, 2023
Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet TherapyChristian Corsini, Hans Garmo, Andri Wilberg Orrason, et al.
BJU International|April 11, 2020
Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in SwedenAndri Wilberg Orrason, Marcus Westerberg, Hans Garmo, et al.
Scandinavian Journal of Urology|March 17, 2026
Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based studyPaolo Zaurito, Rolf Gedeborg, Hans Garmo, et al.
Acta Oncologica (Stockholm, Sweden)|September 19, 2019
Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based studyMarcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, et al.
Pageof 6